The DOI matches its Crossref record; 146 of the 147 references it cites were found in a registry or an index.
Aβ Oligomers – a decade of discovery
Open accessAbstract
Converging lines of evidence suggest that progressive accumulation of the amyloid β‐protein (Aβ) plays a central role in the genesis of Alzheimer’s disease, but it was long assumed that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic Aβ peptides, cell culture models, β‐amyloid precursor protein transgenic mice and human brain to suggest that pre‐fibrillar, diffusible assemblies of Aβ are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the preformed Aβ42 fibrils, no significant cell toxicity was observed in either the absence or presence of Cu2+ (Figure 9, lanes 1 and 2), supporting the previously reported diminished toxicity of Aβ42 fibrils.5,7,54−56”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“which was also shown to form neurotoxic soluble Aβ oligomers.18–20”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“This is confirmed by the decreased cell survival of 44±8% in presence of soluble Aβ42 oligomers (Figure 11, lane 2), supporting the increased neurotoxicity of Aβ42 oligomers versus Aβ42 fibrils.16,19”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“the Aβ42 peptide was employed in these studies because it was shown to form neurotoxic soluble Aβ oligomers.5,8,48”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 4×
“…performance in a hippocampaldependent contextual fear conditioning assay, decreased spine density in the dentate gyrus, and impairment of long-term potentiation (LTP) at ages long before the first apparent detection of Ab dodecamer (Dineley et al. 2002; Jacobsen et al. 2006; Lesne et al. 2006).”
BackgroundInfluentialRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Self-citationTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 3×
“The initial cleavage leading to amyloid b-protein (Ab) production is mediated by the aspartyl protease, b-secretase (also called b-amyloid cleaving enzyme-1, BACE-1), and occurs immediately N-terminal to the Ab domain, simultaneously generating APPsb and the membranetethered C-terminal fragment, C99 (Vassar et al. 199…”
Background
Flagged first, then by citations
1 of the 147 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Selkoe D. J., 2003, Annu. Rev. Pharmacol. Toxicol., 545
- Shankar G. M., 2007, Natural oligomers of the Alzheimer amyloid beta‐protein induce hippocampal synapse loss but can be neutralized by antibodies and small molecules, J. Neurosci.
Cited by
Sorted by citations
Items 401–500 of 1,010
Altered Gray Matter Structural Covariance Networks in Early Stages of Alzheimer's Disease
Montembeault, M., Rouleau, I., Provost, J.-S., & Brambati, S. M. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv105 · Cited by 94
Deng, H., & Mi, M. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1950-9 · Cited by 96
Disentangling Mitochondria in Alzheimer’s Disease
Johri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111520 · Cited by 103
Guillot‐Sestier, M., Sunyach, C., Ferreira, S. T., Marzolo, M., Bauer, C., Thevenet, A., & Checler, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323626 · Cited by 103
Roles of glial cells in synapse development
Pfrieger, F. W. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0005-7 · Cited by 97
Microtubule Dynamics in Neuronal Development, Plasticity, and Neurodegeneration
Penazzi, L., Bakota, L., & Brandt, R. (2015) · International review of cytology · doi:10.1016/bs.ircmb.2015.09.004 · Cited by 97
Strang, F., Scheichl, A., Chen, Y., Wang, X., Htun, N., Bassler, N., Eisenhardt, S. U., Habersberger, J., & Peter, K. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00539.x · Cited by 94
Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V., & Sierks, M. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.068 · Cited by 96
Socodato, R., Portugal, C. C., Canedo, T., Rodrigues, A., Almeida, T. O., Henriques, J. F., Vaz, S. H., Magalhães, J., Silva, C. M., Baptista, F. I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107796 · Cited by 94
Garbuz, D. G., Zatsepina, O. G., & Evgen’ev, M. B. (2021) · Molecular Biology · doi:10.1134/s002689332104004x · Cited by 95
Dysregulation of Calcium Homeostasis in Alzheimer’s Disease
Small, D. H. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9960-5 · Cited by 96
Park, J., Choi, H., Min, J., Kim, B., Lee, S., Yun, J. W., Choi, M., Chang, K., & Lee, D. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.12984 · Cited by 93
Short‐term modern life‐like stress exacerbates Aβ‐pathology and synapse loss in 3xTg‐ AD mice
Baglietto‐Vargas, D., Chen, Y., Suh, D., Ager, R. R., Rodríguez‐Ortiz, C. J., Medeiros, R., Myczek, K., Green, K. N., Baram, T. Z., & LaFerla, F. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13195 · Cited by 97
Sarkar, B., Mithu, V. S., Chandra, B., Mandal, A., Chandrakesan, M., Bhowmik, D., Madhu, P. K., & Maiti, S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402636 · Cited by 93
Chong, S., & Ham, S. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00032 · Cited by 96
Lord, A., Englund, H., Söderberg, L., Tucker, S. M., Clausen, F., Hillered, L., Gordon, M. N., Morgan, D., Lannfelt, L., Pettersson, F. E., et al. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06836.x · Cited by 92
Flammang, B., Pardossi-Piquard, R., Sévalle, J., Debayle, D., Dabert-Gay, A.-S., Thévenet, A., Lauritzen, I., & Checler, F. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112186 · Cited by 85
Parthsarathy, V., McClean, P. L., Hölscher, C., Taylor, M., Tinker, C. L., Jones, G., Kolosov, O., Salvati, E., Gregori, M., Masserini, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054769 · Cited by 96
Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer’s Drug Discovery
Bu, X., Rao, P. P. N., & Wang, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9301-4 · Cited by 97
Gama Sosa, M. A., Gasperi, R. D., Rocher, A. B., Wang, A. C.-J., Janssen, W. G. M., Flores, T., Perez, G. M., Schmeidler, J., Dickstein, D. L., Hof, P. R., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090482 · Cited by 92
Liu, C., Sawaya, M. R., Cheng, P.-N., Zheng, J., Nowick, J. S., & Eisenberg, D. S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja200222n · Cited by 98
He, Y., Cui, J., Lee, J. C., Ding, S., Chalimoniuk, M., Simonyi, Á., Sun, A. Y., Gu, Z., Weisman, G. A., Wood, W. G., et al. (2011) · ASN NEURO · doi:10.1042/an20100025 · Cited by 95
Park, G., Nhan, H. S., Tyan, S.-H., Kawakatsu, Y., Zhang, C., Navarro, M., & Koo, E. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107839 · Cited by 93
Phosphorylated Tau: Toxic, Protective, or None of the Above
Castellani, R. J., Nunomura, A., Lee, H., Perry, G. L., & Smith, M. A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14404 · Cited by 94
Gomes, L. M., Vieira, R. P., Jones, M. R., Wang, M. C. P., Dyrager, C., de Souza-Fagundes, E. M., Silva, J. G. D., Storr, T., & Beraldo, H. D. O. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.04.011 · Cited by 94
Kinetics of spontaneous filament nucleation via oligomers: Insights from theory and simulation
Šarić, A., Michaels, T. C. T., Zaccone, A., Knowles, T. P. J., & Frenkel, D. (2016) · The Journal of Chemical Physics · doi:10.1063/1.4965040 · Cited by 88
Amyloid-β Immunotherapy for Alzheimers Disease
Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 92
Brain Activation of SIRT1: Role in Neuropathology
Paraíso, A. F., Mendes, K. L., & Santos, S. H. S. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8459-x · Cited by 91
New Insights in Amyloid Beta Interactions with Human Telomerase
Wang, J., Zhao, C., Zhao, A., Li, M., Ren, J., & Qu, X. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511030s · Cited by 90
Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., & Panza, F. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.93 · Cited by 93
Merlo, S., Spampinato, S. F., & Sortino, M. A. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.059 · Cited by 94
Copper imbalance in Alzheimer’s disease: Convergence of the chemistry and the clinic
Kepp, K. P., & Squitti, R. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.06.018 · Cited by 93
Kerchner, G. A., & Boxer, A. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.493872 · Cited by 92
Protective Effects of Positive Lysosomal Modulation in Alzheimer's Disease Transgenic Mouse Models
Butler, D., Hwang, J., Estick, C., Nishiyama, A., Kumar, S. S., Baveghems, C. L., Young-Oxendine, H. B., Wisniewski, M. L., Charalambides, A., & Bahr, B. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020501 · Cited by 92
Zempel, H., & Mandelkow, E. (2011) · Neurodegenerative Diseases · doi:10.1159/000332816 · Cited by 90
Amyloid imaging in Alzheimer's disease
Nordberg, A. K. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.03.020 · Cited by 92
Kim, Y. S., Lee, K. J., & Kim, H. (2017) · Psychogeriatrics · doi:10.1111/psyg.12218 · Cited by 92
Low‐n oligomers as therapeutic targets of Alzheimer’s disease
Ono, K., & Yamada, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07187.x · Cited by 76
Amyloid-β-induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins
Bate, C., & Williams, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248724 · Cited by 93
Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease
Andersen, O. M., Rudolph, I.-M., & Willnow, T. E. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1615-4 · Cited by 83
Effect of the Tottori Familial Disease Mutation (D7N) on the Monomers and Dimers of Aβ40and Aβ42
Man, V. H., Nguyen, P. H., Ngô, S. T., Li, M. S., & Derreumaux, P. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400110d · Cited by 89
Fox, L. M., William, C. M., Adamowicz, D. H., Pitstick, R., Carlson, G. A., Spires-Jones, T. L., & Hyman, B. T. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318220a658 · Cited by 88
Cerebrospinal Fluid Aβ42, Phosphorylated Tau181, and Resting-State Functional Connectivity
Wang, L. Y., Brier, M. R., Snyder, A. Z., Thomas, J., Fagan, A. M., Xiong, C., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., & Ances, B. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3253 · Cited by 90
Simvastatin therapy prevents brain trauma‐induced increases in β‐amyloid peptide levels
Abrahamson, E. E., Ikonomović, M. D., Dixon, C. E., & DeKosky, S. T. (2009) · Annals of Neurology · doi:10.1002/ana.21731 · Cited by 89
Watzky, M. A., Morris, A. M., Ross, E. D., & Finke, R. G. (2008) · Biochemistry · doi:10.1021/bi800726m · Cited by 88
Maurice, T., Mustafa, M.-H., Desrumaux, C. M., Keller, E., Naert, G., García-Barceló, M. D. L. C., Cruz, Y. R., & Rodríguez, J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494939 · Cited by 92
The missing link in the amyloid cascade of Alzheimer’s disease – Metal ions
Tiiman, A., Palumaa, P., & Tõugu, V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.023 · Cited by 92
Rahimi, F., Shanmugam, A., & Bitan, G. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533358 · Cited by 88
Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples
Watt, A. D., Perez, K. A., Rembach, A., Sherratt, N. A., Hung, L. W., Johanssen, T., McLean, C., Kok, W. M., Hutton, C. A., Fodero‐Tavoletti, M. T., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1083-z · Cited by 88
D’Souza, Y., Elharram, A., Soon-Shiong, R., Andrew, R. D., & Bennett, B. M. (2015) · Molecular Brain · doi:10.1186/s13041-015-0117-y · Cited by 87
Chung, Y. J., Lee, B. I., Ko, J. W., & Park, C. B. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201500964 · Cited by 87
L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer’s Disease
Polis, B., Srikanth, K. D., Elliott, E., Gil-Henn, H., & Samson, A. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0669-5 · Cited by 79
Inestrosa, N. C., Godoy, J. A., Vargas, J., Arrázola, M. S., Ríos, J. A., Carvajal, F. J., Serrano, F. G., & Farı́as, G. G. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8242-1 · Cited by 89
Prangkio, P., Yusko, E. C., Sept, D., Yang, J., & Mayer, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047261 · Cited by 88
Alzheimer's disease: a mathematical model for onset and progression
Bertsch, M., Franchi, B., Marcello, N., Tesi, M. C., & Tosin, A. (2017) · PORTO Publications Open Repository TOrino (Politecnico di Torino) · Cited by 87
Lee, S. H., Kim, K.-R., Ryu, S.-Y., Son, S., Hong, H. S., Mook-Jung, I., Lee, S.-H., & Ho, W.-K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0465-12.2012 · Cited by 86
Uddin, M. S., Kabir, M. T., Tewari, D., Mathew, B., & Aleya, L. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.134836 · Cited by 83
Role of Flavonoids in Neurodegenerative Diseases: Limitations and Future Perspectives
Maan, G., Sikdar, B., Kumar, A., Shukla, R., & Mishra, A. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200416085330 · Cited by 85
Haghani, M., Shabani, M., Javan, M., Motamedi, F., & Janahmadi, M. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000338494 · Cited by 86
Neurogenesis in mouse models of Alzheimer's disease
Chuang, T. T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.008 · Cited by 88
Gold Nanoparticles and Microwave Irradiation Inhibit Beta-Amyloid Amyloidogenesis
Araya, E., Olmedo, I., Bastús, N. G., Guerrero, S., Puntes, V., Giralt, E., & Kogan, M. J. (2008) · Nanoscale Research Letters · doi:10.1007/s11671-008-9178-5 · Cited by 86
Amino Acid Position-specific Contributions to Amyloid β-Protein Oligomerization
Maji, S. K., Loo, R. R. O., Inayathullah, M., Spring, S. M., Vollers, S. S., Condron, M. M., Bitan, G., Loo, J. A., & Teplow, D. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.038133 · Cited by 86
Mitochondrial quality control and neurological disease: an emerging connection
de Castro, I. P., Martins, L. M., & Tufi, R. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001456 · Cited by 92
Rivera, D. S., Lindsay, C. B., Codocedo, J. F., Morel-Letelier, I., Pinto, C., Cisternas, P., Bozinovic, F., & Inestrosa, N. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.021 · Cited by 84
Mitochondrial Abnormalities in Alzheimer’s Disease
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Cardoso, S. M., & Swerdlow, R. H. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00003-9 · Cited by 86
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation
Freir, D. B., Fedriani, R., Scully, D., Smith, I. M., Selkoe, D. J., Walsh, D. M., & Regan, C. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.01.001 · Cited by 85
Self-citationAβ oligomers trigger and accelerate Aβ seeding
Katzmarski, N., Ziegler‐Waldkirch, S., Scheffler, N., Witt, C. C., Abou‐Ajram, C., Nuscher, B., Prinz, M., Haass, C., & Meyer‐Luehmann, M. (2019) · Brain Pathology · doi:10.1111/bpa.12734 · Cited by 86
Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression?
Small, D. H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.006 · Cited by 83
Soluble Prion Protein Inhibits Amyloid-β (Aβ) Fibrillization and Toxicity
Nieznański, K., Choi, J.-K., Chen, S., Surewicz, K. A., & Surewicz, W. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.400614 · Cited by 90
Roselli, F., Hutzler, P., Wegerich, Y., Livrea, P., & Almeida, O. F. X. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006011 · Cited by 88
Lee, C., & Ham, S. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21628 · Cited by 84
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
Zou, K., Abdullah, M., & Michikawa, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030085 · Cited by 87
Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment
Nadezhdin, K. D., Bocharova, O. V., Bocharov, E. V., & Arseniev, A. S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.062 · Cited by 84
Sierks, M. R., Chatterjee, G., McGraw, C. E., Kasturirangan, S., Schulz, P., & Prasad, S. (2011) · Integrative Biology · doi:10.1039/c1ib00018g · Cited by 84
Fossati, S., Cam, J. A., Meyerson, J. L., Mezhericher, E., Romero, I. A., Couraud, P., Weksler, B. B., Ghiso, J. A., & Rostagno, A. A. (2009) · The FASEB Journal · doi:10.1096/fj.09-139584 · Cited by 86
Cotinine Reduces Amyloid-β Aggregation and Improves Memory in Alzheimer's Disease Mice
Echeverría, V., Zeitlin, R., Burgess, S., Patel, S. P., Barman, A., Thakur, G., Mamcarz, M., Wang, L., Sattelle, D. B., Kirschner, D. A., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102136 · Cited by 85
Age and amyloid-related alterations in default network habituation to stimulus repetition
Vannini, P., Hedden, T., Becker, J. A., Sullivan, C., Putcha, D., Rentz, D. M., Johnson, K. A., & Sperling, R. A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.003 · Cited by 86
Kim, B., Park, J., Chang, K., & Lee, D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.11.015 · Cited by 86
γ-Secretase Catalyzes Sequential Cleavages of the AβPP Transmembrane Domain
Xu, X. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0957 · Cited by 84
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
Autoantibody-catalyzed Hydrolysis of Amyloid β Peptide
Taguchi, H., Planque, S. A., Nishiyama, Y., Symersky, J., Boivin, S., Szabo, P., Friedland, R. P., Ramsland, P. A., Edmundson, A. B., Weksler, M. E., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707983200 · Cited by 81
Fodero‐Tavoletti, M. T., Villemagne, V. L., Paterson, B. M., White, A. R., Li, Q., Camakaris, J., O'Keefe, G. J., Cappai, R., Barnham, K. J., & Donnelly, P. S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1359 · Cited by 83
Surface chemistry of Alzheimer's disease: A Langmuir monolayer approach
Thakur, G., Mićić, M., & Leblanc, R. M. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.07.043 · Cited by 85
Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice
Fragkouli, A., Tsilibary, E. C., & Tzinia, A. K. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.021 · Cited by 90
The MAPT H1 haplotype is associated with tangle-predominant dementia
Santa‐María, I., Haggiagi, A. M., Liu, X., Wasserscheid, J., Nelson, P. T., Dewar, K., Clark, L. N., & Crary, J. F. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1017-1 · Cited by 88
Preclinical Alzheimer disease: Brain oxidative stress, Aβ peptide and proteomics
Aluise, C. D., Sowell, R. A., Beckett, T. L., Murphy, M. P., Cai, J., Pierce, W. M. J., Markesbery, W. R., & Butterfield, D. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.04.011 · Cited by 83
Two decades of new drug discovery and development for Alzheimer's disease
Liu, Z., Zhang, A., Sun, H. J., Han, Y., Kong, L. D., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 84
Yang, S., Wang, W., Ling, T.-J., Feng, Y., Du, X., Zhang, X., Sun, X., Zhao, M., Xue, D., & Yang, Y. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.09.011 · Cited by 82
Kawahara, M., Ohtsuka, I., Yokoyama, S., Kato‐Negishi, M., & Sadakane, Y. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/304583 · Cited by 83
Calviello, G., Su, H., Weylandt, K. H., Fasano, E., Serini, S., & Cittadini, A. R. M. (2013) · BioMed Research International · doi:10.1155/2013/743171 · Cited by 81
Ten Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160550 · Cited by 83
Loeffler, D. A. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230025 · Cited by 90
Understanding BACE1: essential protease for amyloid-β production in Alzheimer’s disease
Stockley, J. H., & O’Neill, C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8271-3 · Cited by 85
Unraveling infectious structures, strain variants and species barriers for the yeast prion [PSI+]
Tessier, P. M., & Lindquist, S. L. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1617 · Cited by 82
Cummings, D. M., Liu, W., Portelius, E., Bayram, S., Yasvoina, M. V., Ho, H., Smits, H., Ali, S. S., Steinberg, R., Pegasiou, C.-M., et al. (2015) · Brain · doi:10.1093/brain/awv127 · Cited by 84
Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease
Oliveira, J. M., Costa, M. G. C., Cachide, M., Silva, O. A. B. D. C. E., & Henriques, A. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170176 · Cited by 84
Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice
Perez, S. E., He, B., Muhammad, N., Oh, K.-J., Fahnestock, M., Ikonomovic, M. D., & Mufson, E. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.002 · Cited by 80
Merlo, S., Spampinato, S. F., & Sortino, M. A. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13050 · Cited by 82
An overview of the genes and biomarkers in Alzheimer’s disease
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Wang, T., Bei, K., Changalath, C., & Rajasekaran, J. J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102599 · Cited by 89
Metadata
- Authors
- Walsh, D. M., & Selkoe, D. J.
- Affiliations
- University College Dublin (IE)
- Brigham and Women's Hospital (US)
- Corresponding author
- Walsh, Dominic M.
- Selkoe, Dennis J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-04
- Volume
- 101
- Issue
- 5
- Pages
- 1172-1184
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1981458288
- Cited by
- 1,938
- References
- 147
- Citations by year
- 2026: 48 · 2025: 36 · 2024: 46 · 2023: 47 · 2022: 50 · 2021: 63 · 2020: 76 · 2019: 81 · 2018: 81 · 2017: 109 · 2016: 120 · 2015: 136 · 2014: 134 · 2013: 159 · 2012: 167
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for Neurologic Diseases
- Wellcome Trust (067660)
- National Institutes of Health
- National Institute on Aging (AG-06173)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease, soluble amyloid-beta, synaptic loss, neuronal injury, amyloid fibrils, amyloid precursor protein, transgenic mouse model
- MeSH terms
- Alzheimer Disease, Humans, Male, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Protein Structure, Secondary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
